BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

14 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

08 Nov 2023 07:00:02 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

25 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

04 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

14 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023

31 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

29 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

01 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia

25 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program

16 May 2023 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference

02 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

14 Mar 2023 16:15:08 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

09 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

23 Feb 2023 07:00:02 By Nasdaq GlobeNewswire